Arcadia Biosciences

Arcadia Biosciences, Inc. is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market. Its crop yield traits are utilized by its partners to develop higher yielding seeds for global crops, including wheat, rice, soybean, corn, and sugarcane, as well as for other crops, such as cotton, turf and trees. The Company's portfolio of agricultural productivity traits includes Nitrogen Use Efficiency (NUE), Water Use Efficiency (WUE), Drought Tolerance (DT), Salinity Tolerance (ST) and Herbicide Tolerance. It has presence in the United States, Africa, India, the United Arab Emirates, Belgium, France and Canada.
Company Growth (employees)
Type
Public
HQ
Davis, US
Size (employees)
57 (est)-28%
Arcadia Biosciences is headquartered in Davis, US

Key People at Arcadia Biosciences

Vic Knauf

Vic Knauf

Chief Scientific Officer
Zhongjin Lu

Zhongjin Lu

Vice President of Product Development
Don Emlay

Don Emlay

Vice President of Regulatory Affairs

Arcadia Biosciences Office Locations

Arcadia Biosciences has an office in Davis
Davis, US (HQ)
105 202 Cousteau Pl

Arcadia Biosciences Data and Metrics

Arcadia Biosciences Financial Metrics

Arcadia Biosciences's revenue was reported to be $3.2 m in FY, 2016 which is a 41% decrease from the previous period.
USD

Revenue (FY, 2016)

3.2 m

Revenue growth (FY, 2015 - FY, 2016), %

(41%)

Net income (FY, 2016)

(19.6 m)

EBIT (FY, 2016)

(18.6 m)

Market capitalization (27-Jun-2017)

21.3 m

Closing share price (27-Jun-2017)

0.5

Cash (31-Dec-2016)

2 m

EV

69.5 m
Arcadia Biosciences's current market capitalization is $21.3 m.
USDFY, 2015FY, 2016

Revenue

5.4 m3.2 m

Revenue growth, %

(41%)

R&D expense

9 m8.7 m

General and administrative expense

11.1 m12.3 m

Operating expense total

21 m21.8 m

EBIT

(15.6 m)(18.6 m)

EBIT margin, %

(287%)(584%)

Interest expense

(2.7 m)(1.3 m)

Pre tax profit

(19.6 m)

Income tax expense

(26 k)(25 k)

Net Income

(18 m)(19.6 m)
USDFY, 2015FY, 2016

Cash

24 m2 m

Accounts Receivable

706 k349 k

Inventories

692 k877 k

Current Assets

52 m52.2 m

PP&E

585 k508 k

Total Assets

74.2 m56.6 m

Accounts Payable

2.4 m2.4 m

Total Debt

49.9 m50.3 m

Current Liabilities

3.5 m3.1 m

Additional Paid-in Capital

172.2 m173.7 m

Retained Earnings

(131.9 m)(151.6 m)

Total Equity

40.2 m22.2 m

Debt to Equity Ratio

1.2 x2.3 x

Debt to Assets Ratio

0.7 x0.9 x

Financial Leverage

1.8 x2.5 x
USDFY, 2015FY, 2016

Net Income

(18 m)(19.6 m)

Depreciation and Amortization

294 k304 k

Accounts Receivable

336 k357 k

Inventories

412 k582 k

Accounts Payable

125 k(19 k)

Cash From Operating Activities

(15.1 m)(17.1 m)

Purchases of PP&E

(151 k)(231 k)

Cash From Investing Activities

(46.4 m)(5.3 m)

Cash From Financing Activities

68.9 m396 k

Interest Paid

2.1 m1 m

Income Taxes Paid

149 k29 k
USDY, 2016

EV/EBIT

-3.7 x

EV/CFO

-4.1 x

Revenue/Employee

39.9 k

Debt/Equity

2.3 x

Debt/Assets

0.9 x

Financial Leverage

2.5 x

Arcadia Biosciences Market Value History

Arcadia Biosciences Company Life and Culture

You may also be interested in